PROLIFERATION IN PRIMARY AND RESTENOTIC CORONARY ATHERECTOMY TISSUE - IMPLICATIONS FOR ANTIPROLIFERATIVE THERAPY
PROLIFERATION IN PRIMARY AND RESTENOTIC CORONARY ATHERECTOMY TISSUE - IMPLICATIONS FOR ANTIPROLIFERATIVE THERAPY
复制标题
DOI：
10.1161/01.res.73.2.223
复制
发表时间：
1993-08-01
影响因子：
20.1
通讯作者：
SCHWARTZ, SM
中科院分区：
文献类型：
--
作者：
OBRIEN, ER;ALPERS, CE;SCHWARTZ, SM
在动脉损伤动物模型的基础上，血管平滑肌细胞增殖已被认为是再狭窄的主要事件。不幸的是，对人类再狭窄病变中的这种增殖知之甚少。本研究的目的是确定原发和再狭窄冠状动脉粥样硬化切除衍生组织中增殖的程度和时间进程。来自211例非连续患者的初次(n=118)和再狭窄(n=100)冠状动脉粥样硬化术标本。用增殖细胞核抗原(增殖细胞核抗原)免疫细胞化学检测动脉粥样硬化切除标本的增殖情况。然后使用免疫组织化学细胞特异性标记物确定增殖细胞核抗原阳性细胞的身份。82%的原发标本和74%的再狭窄标本未见增殖细胞核抗原标记。剩下的大多数标本每张玻片上只有少量的增殖细胞核抗原阳性细胞(通常
On the basis of animal models of arterial injury, smooth muscle cell proliferation has been posited as a dominant event in restenosis. Unfortunately, little is known about this proliferation in the human restenotic lesion. The purpose of this study was to determine the extent and time course of proliferation in primary and restenotic coronary atherectomy-derived tissue. Primary (n=118) and restenotic (n=100) coronary atherectomy specimens were obtained from 211 nonconsecutive patients. Immunocytochemistry for the proliferating cell nuclear antigen (PCNA) was used to gauge proliferation in the atherectomy specimens. The identity of PCNA-positive cells was then determined using immunohistochemical cell-specific markers. Eighty-two percent of primary specimens and 74% of restenotic specimens had no evidence of PCNA labeling. The majority of the remaining specimens had only a modest number of PCNA-positive cells per slide (typically